All In Biotech

Drug Trial Radar · NCT06423352

A Study to Evaluate Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

A Phase 1/2, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacodynamics, and Pharmacokinetics of Zilebesiran in Japanese Patients With Mild to Moderate Hypertension

Last checked: Nov 20, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

36

Actual

Start

Jun 5, 2024

Primary completion

Jul 17, 2025

Study completion Jul 17, 2025

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
May 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacodynamics (PD) and pharmacokinetics (PK) of zilebesiran in Japanese patients with mild to moderate hypertension.

Conditions

  • Mild to Moderate Hypertension

Interventions

  • ZilebesiranDrug

    Zilebesiran administered by subcutaneous (SC) injection

  • PlaceboDrug

    Placebo administered by SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Up to 12 months

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Fukuoka, Japan

  • Clinical Trial Site

    Osaka, Japan

  • Clinical Trial Site

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.